Prominent expression of MAX and MEG3, despite lack of mutations in MAX, suggest a potential role for 14q genes in pituitary adenomas
Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Raúl M. Luque(Instituto de Salud Carlos III), Márta Korbonits(Queen Mary University of London), Esther Rivero‐Cortés(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Mónica Marazuela(Centro de Investigación Biomédica en Red), Paloma Rodriguez Poyo-Guerrero, Cristina Álvarez‐Escolá(Hospital Universitario La Paz), Inmaculada Gavilán-Villarejo(Hospital Universitario Puerta del Mar), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Mercedes Robledo(Spanish National Cancer Research Centre), Rocío Letón, Alfonso Soto‐Moreno(Instituto de Biomedicina de Sevilla), María Ángeles Gálvez-Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 0
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
|The Journal of Clinical Endocrinology & Metabolism|2019|363
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251
Germline<i>NF1</i>Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1
|The Journal of Clinical Endocrinology & Metabolism|2007|136